BostonGene Corporation announced today that it will participate in and present at Immuno-Oncology 360°, taking place February 7 – 10 in Brooklyn, New York.
BostonGene session details can be found below:
Elucidation of the Cellular and Molecular Features of the TME Underlying Immune Escape and IO Failure
Thursday, February 9 | 4:50 PM ET
Speaker: Michael Goldberg, PhD, Director of Immunology, BostonGene
This session will address BostonGene’s comprehensive profile of a patient’s disease for therapy selection and stratification for IO clinical trials to improve outcomes by using CLIA-certified advanced whole exome and whole transcriptome sequencing paired with deep immunoprofiling and best-in-class analytics.
“With BostonGene’s transcriptional profiling and sophisticated analytics, we can perform detailed surveys of functional immune programs in the tumor microenvironment. Our comprehensive genomic profiling platform and cutting-edge bioinformatics can stratify patients into IO response groups and pair individuals with the most effective therapy,” said Michael Goldberg, PhD, Director of Immunology at BostonGene. “I look forward to participating at IO360° and to presenting how our expanded framework that evaluates immune escape mechanisms within the TME could facilitate the rational design of IO combinations to improve patient outcomes.”
About BostonGene Corporation
BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait™ Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor Portrait™ Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005297/en/
Source: BostonGene Corporation
View this news release online at:
http://www.businesswire.com/news/home/20230207005297/en
